Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
2.110
-0.010 (-0.47%)
At close: Jan 22, 2025, 4:00 PM
2.100
-0.010 (-0.47%)
Pre-market: Jan 23, 2025, 8:03 AM EST
Immuneering Stock Forecast
IMRX's stock price has decreased by -64.3% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Immuneering stock have an average target of 12.8, with a low estimate of 3.00 and a high estimate of 25. The average target predicts an increase of 506.64% from the current stock price of 2.11.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Immuneering stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
Buy | 2 | 1 | 1 | 1 | 1 | 1 |
Hold | 3 | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 8 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +610.90% | Jan 13, 2025 |
Chardan Capital | Chardan Capital | Strong Buy Maintains $13 | Strong Buy | Maintains | $13 | +516.11% | Jan 8, 2025 |
Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +610.90% | Jan 7, 2025 |
Chardan Capital | Chardan Capital | Strong Buy Maintains $13 | Strong Buy | Maintains | $13 | +516.11% | Nov 20, 2024 |
Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +610.90% | Nov 14, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.93
from -1.88
EPS Next Year
-1.71
from -1.93
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | n/a | n/a | n/a | |||
Avg | n/a | n/a | n/a | |||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | -1.74 | -0.97 | -1.28 | |||
Avg | -1.93 | -1.71 | -2.09 | |||
Low | -2.04 | -2.31 | -2.48 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.